Havila Kystruten AS reports a solid operational performance for Q4 2024 and January 2025, reflecting steady demand and continued improvements in ...
Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical-stage biotechnology company developing novel immunotherapies against cancer, announces its fourth quarter 2024 results today. Conference call and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback